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SUMMARY The new analysis of the expression of cell cycle regulators (used in 
various neoplasms) and the nominal immunohistologic assays still represent 
valid and feasible diagnostic methods in most pathology practice. We examined 
114 paraffin-embedded histologic specimens of melanocytic cutaneous lesions. 
The primary objective of this study was to explore diagnostic potential of the 
two important cell cycle regulators, p16 and Ki67, also evaluating the variations 
of expression by use of a semi quantitative graded scale. Another aim was to 
study the hypothetical correlation between p16 expression (in melanocytic and 
non-melanocytic lesions) and two independent variables, i.e. patient age and an-
atomical sites (sun exposed or non-sun exposed) of the lesions. Cell population 
was considered positive for antibody-specific p16 and Ki67 when at least 33% of 
the cells showed well-defined nuclear and/or cytoplasmic staining. A special p16 
and Ki67 trend was found only in Spitz nevus, atypical Spitz nevus and invasive 
malignant melanoma (MM). No discriminative values were found regarding oth-
er lesions (junctional melanocytic nevus, MM in situ, superficially spreading MM, 
non-melanoma skin cancers). p16 was over-expressed on sun exposed sites and 
hypo-expressed on non-sun exposed areas, yielding a statistically significant cor-
relation (p<0.03). According to patient age, p16 was over-expressed in patients 
aged ≥61 and hypo-expressed in patients aged ≤60 (p=0.09).
KEY woRdS: melanocytic lesions, p16 protein, Ki67 protein, malignant mela-
noma, cell cycle regulators, non-melanocytic skin cancers, predictive factors
INTRodUCTIoN
The cell cycle (controlled by several checkpoints) 
plays an important role in the pathogenesis of many 
cancers. Melanoma and non-melanoma skin can-
cers are an important global health problem, for this 
reason early detection and surgical excision of the 
tumors represent the principal goals. The immuno-
histochemistry progress can play an important role 
to improve histologic diagnosis. In this regard, the 
new analysis of the expression of cell cycle regulators 
(used in various neoplasms) and the nominal immu-
nohistologic assays still represent valid and feasible 
diagnostic methods in the pathology practice (1).
Starting from previous studies, we decided to of-
fer another point of view on the use of two important 
cell cycle regulators. The primary objective of this 
study was to explore diagnostic potential of the two 
important cell cycle regulators, p16 and Ki67, also 
evaluating the variations of their expression, using 
a semi quantitative graded scale. Another aim was 
to study the hypothetical correlation between p16 
expression (in melanocytic and non-melanocytic le-
sions) and two independent variables, i.e. patient 
age and anatomical area (sun exposed or non-sun 
exposed) of the lesions analyzed.
150 ACTA DERMATOVENEROLOGICA CROATICA
Donati et al.      Acta Dermatovenerol Croat
p16 and Ki67 in skin cancers    2013;21(3):
MATERIALS ANd METodS
We examined 114 paraffin-embedded histologic 
specimens of melanocytic and non-melanocytic cu-
taneous lesions, which were stored at the Dermato-
pathology Unit of our Institute. Melanocytic lesions 
included melanocytic nevus (MN), Spitz nevus (SN), 
atypical Spitz nevus (ASN) and malignant melanoma 
(MM), while non-melanocytic lesions (NMC) included 
basal cell carcinoma (BCC) and squamous cell carci-
noma (SCC). Five groups were analyzed.
Specimens were fixed in 10% buffered formalin. 
The sections were routinely processed and embedded 
in paraffin. Where necessary, in addition to hematoxy-
lin-eosin staining, conventional immunohistologic 
stains (S100, HMB45, Melan-A) were performed.
In all histologic samples, double staining with p16 
and Ki67 proteins was performed using a commercial 
immunohistochemical kit, normally used for simulta-
neous qualitative detection of p16 and Ki67 proteins 
in cervical cytology preparations. The distinct reaction 
products analyzed were brown and red. The brown 
staining of cells (cytoplasm and/or nuclei) indicates 
p16 expression, while red staining of cells (nuclei) in-
dicates Ki67 expression (Fig. 1a). Cells stained for both 
antigens exhibit brown cytoplasmic staining with typi-
cally pronounced red nuclei.
Cell population was considered positive for anti-
body-specific p16 and Ki67 when at least 33% of the 
cells showed well-defined nuclear and/or cytoplasmic 
staining; for this reason, we arbitrarily used an accurate 
semi-quantitative graded scale, as follows: 0%; 0%-
11%; 12%-22%; 23%-33%; 34%-66%; and 67%-100%.
Then, we evaluated if two independent variables 
could be predictive factors for p16 expression (either 
p16 over- or hypo-expression). To establish predictors, 
we analyzed age (≤60 or ≥61 years) and if the primary 
cutaneous lesions were present on sun exposed or 
non-sun exposed areas. Sun exposed sites were the 
face, neck, scalp (if absence of hairs) and back of the 
hands. 
Assuming that the effects of the predictor vari-
ables were constant over time, we used Spearman’s 
coefficient between p16 expression rate and the pre-
dictors (age and presence or absence of lesions on 
sun exposed areas).




Out of 114 study patients, 63 (55.3%) were males 
and 51 (44.7%) females; median age of the entire co-
hort was 42 years. Melanocytic nevus was diagnosed 
in 29 males and 25 females (median age 42.81 years), 
MM in seven males and six females (median age 44.3 
years), ASN in six males and five females (median age 
35.6 years), and SN in six males and three females 
(median age 36.5 years. Regarding NMC, there were 
23 (85.2%) BCC and four (14.8%) SCC. Eleven patients 
were female and 16 male (median age 60.5 years).
Fifty-four (47.4%) histologic samples correspond-
ed to MN, 13 (11.4%) to MM, 11 (9.6%) to ASN, 9 (7.9%) 
to SN and 27 (23.7%) to NMC. Among MN, histopath-
ologic analysis showed 17 (31.48%) junctional MN, 
30 (55.55%) compound MN, 3 (5.55%) dermal MN, 3 
(5.55%) dysplastic MN and 1 (1.84%) desmoplastic 
MN. Regarding MM, 10 (76.92%) were superficially 
spreading and 3 (23.08%) were invasive MM. Breslow 
thickness ranged between 0.4 mm and 1.4 mm.
P16 and Ki67 analysis
In 37 of 54 MN, the percentage of p16 positive 
cells was medium strong, between 34% and 100%; 
in all cases, the intensity was the same throughout 
the lesion thickness. The remaining 17 MN showed a 
medium low staining intensity (12%-33%). Regarding 
Ki67, 42 lesions showed low intensity (ranging be-
tween 0% and 22%), while the remaining 12 lesions 
showed a wide range of positivity (between 34% and 
100%), with poor discriminative results (Fig. 1a,  b). 
All 9 cases of SN were positive (≥33%) on stain-
ing for p16 and the cellular immune reaction was very 
strong (ranging between 67% and 100%) in 7 cases. 
Concerning Ki67, cellular reactivity was always medi-
um (between 23% and 34%), but slightly higher than 
the majority of MN (Fig. 1c).
All 11 cases of ASN were positive for p16 and Ki67 
staining and the immune reaction ranged between 
34% and 66%, while Ki67 also showed cellular posi-
tivity between 34% and 66% (Fig. 1d). In these cases, 
p16 immune reaction was lower and Ki67 higher as 
compared with SN.
Regarding MM, we found double p16 cellular 
positivity: between 0% and 33% (in 6 cases) and be-
tween 34% and 100% (in 7 cases). In the first group, 
we recorded very low values of p16 (0%-11%) only in 
invasive MM; in these cases, p16 decreased progres-
sively in the dermal melanocytic population. Regard-
ing Ki67, histologic specimens showed high positivity 
(67%-100%) only in invasive MM (Fig. 2a). Finally, in 
NMC lesions, we found a high prevalence (69.6% of 
all NMC lesions) of lesions with p16 expression be-
tween 34% and 66% (Fig. 2b), while the remaining 
specimens showed p16 expression ≤34%. Regarding 
Ki67, 71.4% of the lesions showed 23%-33% positiv-
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ity, while the remaining 28.6% of the lesions showed 
expression of 0%-11%.
Accordingly, a special p16 and Ki67 trend was 
found only in SN, ASN and invasive MM, whereas in 
other lesions (junctional MN, in situ MM, superficially 
spreading MM, NMC), no discriminative values were 
found.
p16 expression according to age and sun 
exposed or non-sun exposed areas
According to age, 28 patients were aged ≥61 and 
87 patients ≤60; the patients aged ≤60 showed a me-
dium p16 expression of 12%-22%, while those aged 
≥61 showed a p16 positivity of 34-66% (p = 0.09; 
Spearman’s coefficient  - 0.158). Regarding anatomi-
cal sites, 45 (39.5%) patients had cutaneous lesions 
removed on sun exposed areas and 69 (60.5%) pa-
tients on non-sun exposed areas. On nonparametric 
Spearman’s coefficient test, we found that lesions re-
moved on sun exposed sites showed p16 expression 
of 34%-66% (Fig. 2b) and those removed on non-sun-
exposed areas showed p16 expression of 12%-22% (p 
< 0.03; Spearman’s coefficient - 0.185).
Briefly, p16 was hyper-expressed on sun exposed 
sites and hypo-expressed on non-sun exposed areas, 
yielding a statistically significant correlation (p<0.03); 
p16 was over-expressed in patients aged ≥61 and 
hypo-expressed in those aged ≤60 (p=0.09).
Figure 1a Figure 1b
Figure 1c Figure 1d
Figure 1. (a) Junctional melanocytic nevus: medium p16 and Ki67 expression. Black arrow indicates Ki67 ex-
pression; red arrow indicates p16 expression (p16-Ki67; X20); (b) dermal nevus: p16 medium high expression 
and Ki67 very low expression (p16-Ki67; X10); (c) Spitz nevus: p16 overexpression and Ki67 medium expression 
(p16-Ki67; X20); (d) atypical Spitz nevus: reduction of p16 expression (compared to dermal and Spitz nevus) and 
medium low Ki67 expression (p16-Ki67; X10).
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dISCUSSIoN
p16 is a protein product of the CDKN2A familial 
melanoma gene. p16 inhibits the G1 cyclin-depen-
dent kinases (CDKs) 4 and 6. In the absence of func-
tional p16, these CDKs phosphorylate and inactivate 
the retinoblastoma tumor suppressor gene product, 
resulting in cell cycle regression and, ultimately, in-
creased cellular proliferation (2,3). In 1995, Pollock 
et al. reported partial and homozygous deletions 
of CDKN2A gene in melanoma cell lines (4). At the 
same time, mutations in other melanoma (MM) cell 
lines were described, occurring most commonly in 
the exon 1 or 2 of the CDKN2A gene located near 
dipyrimidine sites, commonly associated with dam-
age with ultraviolet rays (5). Reed et al. and Talve et al. 
were the first to report that the p16 loss was related 
to the depth of invasion (6,7). These results were also 
confirmed in our invasive MM samples.
In current analysis, most MN, in situ MM and su-
perficially spreading MM showed a medium high 
p16 cellular positivity, without a discriminative value. 
However, a recent study speculates that p16 inacti-
vation is not strictly timed event in MM tumor gen-
esis and that it is not always inactivated in the MM 
cancer sequence (8). In this regard, it is also impor-
tant to emphasize that p16 positivity in superficially 
spreading MM could also reassure the pathologist on 
the possible superficial localization of the malignant 
cells and, therefore, on a lower rate of recurrence and 
metastases.
We speculate that this can be valid, especially for 
questionable lesions of about 1.00 mm of Breslow 
thickness and/or with an important inflammatory in-
filtrate. In a previous analysis, no correlation of p16 
decreasing score was found with Breslow thickness, 
but only with increasing stage (9). In the current 
study, however, we found the loss of p16 to increase 
with increasing Breslow thickness and depth of mela-
nocytic lesions.
Ki67 is a nuclear protein present in two isoforms: 
345 kDa and 395 kDa, and it is expressed by prolifer-
ating cells in late G1, S, G2 and M phases, but not in 
G0 phase (10). In our cohort, we found a proportional 
increase of Ki67 staining from benign to malignant 
melanocytic lesions. An exceptional trend was high-
lighted. In fact, 77.7% of MN and SN showed a very 
low Ki67 cellular positivity, while ASN and invasive 
MM showed strong cellular positivity (these values 
were not maintained in superficial MM).
Distinction between ASN and MM remains one 
of the most important areas in pathology. Although 
ASN have generally been reported to have a good 
prognosis, well documented cases of metastases and 
death exist. For the malignant potential of these le-
sions, clinicians often make decisions to treat them as 
MM, also performing sentinel lymph node (11). In this 
regard, p16 and Ki67, used in conjunction, can give 
further help in the discrimination of these lesions, es-
pecially when evaluated in the same tissue samples.
Regarding NMC, the analysis detected p16 protein 
in 69.6% of the lesions, ranging between 34% and 
66%, while Ki67 expression was medium low (22%-
33%) in 71.4% of the lesions. All these results were 
similar to those reported by other authors (12-14). 
In our study, no case of invasive NMC was found. Ac-
cording to previous studies (12-15) and our report, we 
think that currently there are too few and discordant 
results on p16 expression in NMC that cannot ascer-
tain correlation between p16 expression and the pos-
Figure 2. (a) Invasive melanoma: loss of p16 expression and high Ki-67 expression of cell population (p16-
Ki67; X20); (b) basal cell carcinoma of sun exposed site (age ≥61) showing p16 hyper-expression (p16-Ki67; 
X10).
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sible malignant progression and/or tumor invasion. 
Further studies with larger samples are required.
Another two important aims of our study were to 
evaluate the correlation between p16 expression and 
age (≤60 and ≥61), and between p16 expression and 
sun exposed or non-sun-exposed areas. Sun exposed 
lesions showed a medium high p16 expression, rang-
ing between 33% and 66%, while no exposed sites 
had lower values (11%-22%); Spearman’s nonpara-
metric test yielded a statistically significant result 
(p<0.03), which was consistent with previous studies 
(15-18). In this regard, we suppose that the overex-
pression in the lesions on exposed sites can be cor-
related with the response of human melanocytes and 
keratinocytes to UVB irradiation and that the relative 
p16 pathway activation is associated with better re-
sponse to a possible invasive malignant process.
Unlike previous studies, we also decided to ex-
plore the possible correlation between p16 expres-
sion and the patient relative age. Among 114 lesions, 
patients aged ≤60 showed a medium p16 expression 
(12%-22%), while it was 33%-66% in patients aged 
≥61 (p=0.09). In a previous work, Nielsen et al. stud-
ied p16 expression in adult and young tissues, and 
found that p16 expression was present in some tis-
sues (such as Langerhans islets in the pancreas, thy-
roid, gland of stomach, and melanocytes in the skin), 
while in younger and infant patients, p16 expression 
was present only in the thymic Hassall’s corpuscles, 
which is the only organ programmed for an early 
senescence progress (19). Although there are no sta-
tistically significant results (p=0.09), according to our 
study, in elderly skin, both the increased susceptibil-
ity to UVB and p16 response to more frequent car-
cinogenic process can play important roles; this can 
explain the higher p16 expression in older than in 
younger tissues, also found in current analysis.
CoNCLUSIoN
A special p16 and Ki67 trend was found only in 
SN, ASN and invasive MM. Sun exposed area showed 
a statistically significant correlation with p16 hyper-
expression; this value was not maintained for the age 
of the patients.
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